Interleukin-23 Inhibitors
For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab. Response to treatment should be evaluated after a 12-week treatment period in psoriasis pati...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2022-04-01
|
| Series: | Turkderm Turkish Archives of Dermatology and Venereology |
| Subjects: | |
| Online Access: | https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&un=TURKDERM-06337&look4= |
| _version_ | 1797915616180436992 |
|---|---|
| author | Esra Adışen |
| author_facet | Esra Adışen |
| author_sort | Esra Adışen |
| collection | DOAJ |
| description | For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab. Response to treatment should be evaluated after a 12-week treatment period in psoriasis patients being treated with IL-23 inhibitors. In patients with partial response, dose increase may be planned, or topical corticosteroids, vitamin D analogs, methotrexate, or phototherapy (UVB) may be added to the treatment. |
| first_indexed | 2024-04-10T12:44:16Z |
| format | Article |
| id | doaj.art-a1161fecd6c04c29b3ab9d2c46f9db0d |
| institution | Directory Open Access Journal |
| issn | 2651-5164 |
| language | English |
| last_indexed | 2024-04-10T12:44:16Z |
| publishDate | 2022-04-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkderm Turkish Archives of Dermatology and Venereology |
| spelling | doaj.art-a1161fecd6c04c29b3ab9d2c46f9db0d2023-02-15T16:14:10ZengGalenos Publishing HouseTurkderm Turkish Archives of Dermatology and Venereology2651-51642022-04-0156Suppl 1616610.4274/turkderm.galenos.2022.06337TURKDERM-06337Interleukin-23 InhibitorsEsra Adışen0https://orcid.org/0000-0002-8768-231XGazi University Faculty of Medicine, Department of Dermatology and Venereology, Ankara, TurkeyFor adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab. Response to treatment should be evaluated after a 12-week treatment period in psoriasis patients being treated with IL-23 inhibitors. In patients with partial response, dose increase may be planned, or topical corticosteroids, vitamin D analogs, methotrexate, or phototherapy (UVB) may be added to the treatment.https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&un=TURKDERM-06337&look4=il-23 inhibitorguselkumabtildrakizumabrisankizumab |
| spellingShingle | Esra Adışen Interleukin-23 Inhibitors Turkderm Turkish Archives of Dermatology and Venereology il-23 inhibitor guselkumab tildrakizumab risankizumab |
| title | Interleukin-23 Inhibitors |
| title_full | Interleukin-23 Inhibitors |
| title_fullStr | Interleukin-23 Inhibitors |
| title_full_unstemmed | Interleukin-23 Inhibitors |
| title_short | Interleukin-23 Inhibitors |
| title_sort | interleukin 23 inhibitors |
| topic | il-23 inhibitor guselkumab tildrakizumab risankizumab |
| url | https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&un=TURKDERM-06337&look4= |
| work_keys_str_mv | AT esraadısen interleukin23inhibitors |